Erasca
ERAS
14.12
-0.18
-1.26%
Erasca
US · ERAS
#2103 by market cap
Listed 2021
14.12
-0.18
-1.26%
Live - 5344 symbols - heartbeat 100s ago
· 2026-10-08 08:28
Pre-market
14.15
+0.21%
After-hours
14.12
0.00%
- Market cap
- 4.94B
- P/E (TTM)i
- -14.86
- P/Bi
- 13.64
- EPSi
- -0.44
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on ERAS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 9.6 percentage points.
Institutional ownership
- Held by institutions
- 81.31% -9.60pp
- Institutions
- 293 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund34.36%
Hedge Fund22.29%
VC/PE Fund20.09%
Individual/Insider9.65%
Public Company2.42%
Private Company0.96%
Sovereign Wealth Fund0.61%
Insurance Company0.38%
Government Pension Fund0.19%
Other9.06%
Top holders as of 2026-06-30
Jonathan Lim
9.25% · 32.36M sh
T. Rowe Price Group, Inc.
7.85% · 27.46M sh
Frazier Life Sciences Management, LP
7.14% · 24.98M sh
BlackRock
6.05% · 21.15M sh
RTW Investments, LP
5.13% · 17.95M sh
VR Management, LLC
5.12% · 17.89M sh
Vanguard Capital Management, LLC
3.75% · 13.10M sh
State Street Global Advisors
3.48% · 12.18M sh
Logos Global Management, L.P.
3.47% · 12.15M sh
Artal Group S.A.
3.26% · 11.40M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 38 buys · 12 sells
| Name | Role | Stake |
|---|---|---|
| Jonathan Lim | Chairperson & CEO | 9.25% |
| Alexander Casdin | Independent Director | 0.19% |
| David Chacko | CFO & Chief Business Officer | 0.08% |
| James Bristol | Independent Director | 0.06% |
| Pratik Multani | Independent Director | 0.05% |
| Ebun Garner | General Counsel | 0.01% |
| Valerie Harding-Start | Independent Director | 0.01% |
| Julie Hambleton | Independent Director | 0.00% |
| Jean I. Liu | Independent Director | -- |
| Michael Varney | Chairman of Research & Development, Scientific Advisory Board member and Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-09 | Charles Fuchs | President of Research & Development | Other Derivative Acquisition | +1,300,000 | $18.12 |
| 2026-06-25 | Jean I. Liu | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Alexander Casdin | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Pratik Multani | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | James Bristol | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Julie Hambleton | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-06-25 | Valerie Harding-Start | Independent Director | Other Derivative Acquisition | +29,888 | $16.01 |
| 2026-03-31 | Ebun Garner | General Counsel | Derivative Exercise and Sale | -80,000 | $1.70–16.40 |
| 2026-03-03 | Shannon Morris | Chief Medical Officer | Derivative Exercise and Sale | -20,000 | $1.70–15.04 |
| 2026-01-28 | Michael Varney | Chairman of Research & Development, Scientific Advisory Board member and Director | Other Derivative Acquisition | +96,000 | $10.31 |
| 2026-01-28 | Jonathan Lim | Chairperson & CEO | Other Derivative Acquisition | +2,000,000 | $10.31 |
| 2026-01-28 | Ebun Garner | General Counsel | Other Derivative Acquisition | +560,000 | $10.31 |
| 2026-01-28 | Shannon Morris | Chief Medical Officer | Other Derivative Acquisition | +625,000 | $10.31 |
| 2026-01-28 | David Chacko | CFO & Chief Business Officer | Other Derivative Acquisition | +640,000 | $10.31 |
| 2026-01-06 | Ebun Garner | General Counsel | Derivative Exercise and Sale | -120,000 | $1.70–5.59 |
| 2025-12-31 | Jean I. Liu | Independent Director | Other Derivative Acquisition | +20,617 | $3.72 |
| 2025-12-31 | Alexander Casdin | Independent Director | Other Derivative Acquisition | +23,872 | $3.72 |
| 2025-12-31 | Pratik Multani | Independent Director | Other Derivative Acquisition | +19,532 | $3.72 |
| 2025-12-31 | James Bristol | Independent Director | Other Derivative Acquisition | +37,762 | $3.72 |
| 2025-12-31 | Valerie Harding-Start | Independent Director | Other Derivative Acquisition | +24,306 | $3.72 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:28:48 · For reference only, not investment advice and not tailored to your situation.